Renalase and blood vessel blockages after heart attack
Part of Heart & circulation clinical trials.
This study is looking at a protein in the blood (renalase) and how it relates to blockages in tiny blood vessels after a heart attack. Researchers want to see if this protein can help predict recovery, which could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a heart attack (STEMI or high-risk NSTEMI) and needed an emergency angioplasty or stenting (PCI).
- If you had a STEMI, your symptoms started less than 48 hours before the procedure.
- If you had an NSTEMI, it was considered high-risk by your doctor.
- You do not have severe kidney disease (GFR less than 20).
- You are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people develop micro-blockages in the heart's small blood vessels after emergency angioplasty (PCI) for a heart attack. If you join, you'll help doctors understand these risks and maybe prevent future problems.
This trial tests whether a blood test looking at platelets and tiny cell particles can help predict future blood clots or bleeding in people who have both chronic kidney disease and a recent heart attack. The goal is to improve treatment safety.
This trial tests treatments for small blood vessel damage after a major heart attack (STEMI). If you have had a heart attack and are receiving a stent, this study may help improve recovery by targeting microvascular injury.
This trial studies whether sacubitril-valsartan works better than enalapril to improve heart healing after a specific type of heart attack. It aims to see if the heart’s shape and pumping recover more effectively.
This trial uses a special ultrasound camera inside the heart's arteries to guide stent placement for people with chronic kidney disease. The goal is to see if this approach improves outcomes compared to standard methods.
This study tests a new kind of coronary stent that slowly releases rapamycin to keep an artery open. You may be invited if you have a small number of specific, treatable blockages and can take the required blood-thinning medicines.
Hear when a new Acute Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.